Advertisement

Management of acquired von Willebrand syndrome

  • Janie Charlebois
    Affiliations
    Division of Hematology/Oncology, Centre Hospitalier Universitaire Sainte-Justine, Department of Pediatrics, Université de Montréal, Montréal, QC, Canada
    Search for articles by this author
  • Georges-Étienne Rivard
    Affiliations
    Division of Hematology/Oncology, Centre Hospitalier Universitaire Sainte-Justine, Department of Pediatrics, Université de Montréal, Montréal, QC, Canada
    Search for articles by this author
  • Jean St-Louis
    Correspondence
    Corresponding author at: Hôpital Maisonneuve-Rosemont, 5415 boul de l'Assomption, Montréal, QC, H1T 2M4, Canada.
    Affiliations
    Division of Hematology/Oncology, Hôpital Maisonneuve-Rosemont, Department of Medicine, Université de Montréal, Montréal, QC, Canada
    Search for articles by this author
Published:October 30, 2018DOI:https://doi.org/10.1016/j.transci.2018.10.012

      Abstract

      Acquired von Willebrand syndrome (AVWS) is a rare acquired bleeding disorder that resembles von Willebrand disease by its clinical symptoms and laboratory findings, but differs by its negative personal and family history of bleeding diathesis. AVWS is mostly seen in the elderly, but it has been described in children, often in those with congenital heart disease and Wilms tumor. It is most commonly associated with lymphoproliferative, myeloproliferative, cardio-vascular, or autoimmune diseases, solid tumors, and certain drugs. The diagnosis should be suspected in a patient who is known for one of these underlying conditions and who presents with new onset of bleeding or who will be undergoing an invasive procedure. Treatment of the underlying condition, when possible, usually results in correction of AVWS. When acute bleeding occurs or the underlying condition is not treated, emphasis should be put on control and prevention of bleeding. Many options are available. DDAVP is the first line of treatment for bleeding. vWF concentrates are used to treat bleeding that is unresponsive to DDAVP and as prophylaxis before procedures. This review summarises current knowledge and reviews the different management options for bleeding.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Transfusion and Apheresis Science
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Mital A.
        Acquired von Willebrand syndrome.
        Adv Clin Exp Med. 2016; 25: 1337-1344
        • Stone M.E.
        • Mazzeffi M.
        • Derham J.
        • Korshin A.
        Current management of von Willebrand disease and von Willebrand syndrome.
        Curr Opin Anaesthesiol. 2014; 27: 353-358
        • Bustany S.
        • Gautier P.
        • Lequerrec A.
        • Troussard X.
        • Ollivier Y.
        • Borel-Derlon A.
        Le syndrome de Willebrand acquis: du diagnostic au traitement.
        Pathol Biol. 2009; 57: 536-542
        • Boissier E.
        • Darnige L.
        • Dougados J.
        • Arlet J.-
        • Dupeux S.
        • Georgin-Lavialle S.
        • et al.
        Syndrome de Willebrand acquis: étude d’une série de neuf patients et revue de la littérature.
        La Revue de Médecine Interne. 2014; 35: 154-159
        • Kumar S.
        • Pruthi R.K.
        • Nichols W.L.
        Acquired von Willebrand disease.
        Mayo Clin Proc. 2002; 77: 181-187
        • Kumar S.
        • Pruthi R.K.
        • Nichols W.L.
        Acquired von Willebrand’s syndrome: a single institution experience.
        Am J Hematol. 2003; 72: 243-247
        • Eikenboom J.C.
        • Tjernberg P.
        • Van Marion V.
        • Heering K.J.
        Acquired von Willebrand syndrome: diagnostic problems and therapeutic options.
        Am J Hematol. 2007; 82: 55-58
        • Tiede A.
        • Rand J.H.
        • Budde U.
        • Ganser A.
        • Federici A.B.
        How I treat the acquired von Willebrand syndrome.
        Blood. 2011; 117: 6777-6785
        • Collins P.
        • Budde U.
        • Rand J.H.
        • Federici A.B.
        • Kessler C.M.
        Epidemiology and general guidelines of the management of acquired haemophilia and von Willebrand syndrome.
        Haemophilia. 2008; 14: 49-55
        • Veyradier A.
        • Jenkins C.S.
        • Fressinaud E.
        • Meyer D.
        Acquired von Willebrand syndrome: from pathophysiology to management.
        Thromb Haemost. 2000; 84: 175-182
        • Tiede A.
        Diagnosis and treatment of acquired von Willebrand syndrome.
        Thrombosis Research. 2012; 130: S2-S6
        • Federici A.B.
        • Rand J.H.
        • Bucciarelli P.
        • Budde U.
        • van Genderen P.J.
        • Mohri H.
        • et al.
        Acquired von Willebrand syndrome: data from an international registry.
        Thromb Haemost. 2000; 84: 345-349
        • Mohri H.
        Acquired von Willebrand syndrome: features and management.
        Am J Hematol. 2006; 81: 616-623
        • Tefferi A.
        • Nichols W.L.
        Acquired von Willebrand disease: concise review of occurrence, diagnosis, pathogenesis, and treatment.
        Am J Med. 1997; 103: 536-540
        • Federici A.B.
        • Budde U.
        • Rand J.H.
        Acquired von Willebrand syndrome 2004: International Registry—diagnosis and management from online to bedside.
        Hamostaseologie. 2004; 24: 50-55
        • Mohri H.
        Acquired von Willebrand syndrome: its pathophysiology, laboratory features and management.
        J Thromb Thrombolysis. 2003; 15: 141-149
        • Federici A.B.
        Therapeutic approaches to acquired von Willebrand syndrome.
        Expert Opin Investig Drugs. 2000; 9: 347-354
        • Clapson P.
        • Bordier E.
        • Grasser L.
        • Merat S.
        • Diraison Y.
        • Gestion Brinquin L.
        Périopératoire d’un patient porteur d’un syndrome de von Willebrand acquis.
        Annales Françaises d’Anesthésie et de Réanimation. 2008; 27: 86-89
        • Michiels J.J.
        • Budde U.
        • van der Planken M.
        • van Vliet H.H.D.M.
        • Schroyens W.
        • Berneman Z.
        Acquired von Willebrand syndromes: clinical features, aetiology, pathophysiology, classification and management.
        Best Pract Res Clin Haematol. 2001; 14: 401-436
        • Avila M.L.
        • Lee K.J.
        • Bouskill V.
        • Rand M.L.
        • James P.
        • Carcao M.
        Acquired von Willebrand syndrome in paediatric patients with congenital heart disease: challenges in the diagnosis and management of this rare condition.
        Haemophilia. 2015; 21: e89-e92
        • Fosbury E.
        • Szychot E.
        • Slater O.
        • Mathias M.
        • Sibson K.
        An 11-year experience of acquired von Willebrand syndrome in children diagnosed with Wilms tumour in a tertiary referral centre.
        Pediatr Blood Cancer. 2017; 64 (Epub 2016 Sep 12)https://doi.org/10.1002/pbc.26246
        • Franchini M.
        • Castaman G.
        • Coppola A.
        • Santoro C.
        • Zanon E.
        • Di Minno G.
        • et al.
        Acquired inhibitors of clotting factors: AICE recommendations for diagnosis and management.
        Blood Transfus. 2015; 13: 498-513
        • Maddox J.M.
        • Anderson J.A.
        • Plews D.
        • Ludlam C.A.
        Management of acquired von Willebrand’s syndrome in a patient requiring major surgery.
        Haemophilia. 2005; 11: 633-637
        • Sardesai M.P.
        • Sabik J.
        • Koch C.G.
        Perioperative management of acquired von Willebrand disease in cardiac surgery: type 2B or not 2B?.
        J. Cardiothoracic Vasc. Anesthesia. 2011; 25: 131-133
        • Kanakry J.A.
        • Gladstone D.E.
        Maintaining hemostasis in acquired von Willebrand syndrome: a review of intravenous immunoglobulin and the importance of rituximab dose scheduling.
        Transfusion. 2013; 53: 1730-1735
        • Colella M.P.
        • Duarte G.C.
        • Marques Jr., J.F.
        • De Paula E.V.
        Haemostatic management of extreme challenges to haemostasis in acquired von Willebrand syndrome.
        Haemophilia. 2012; 18: e188-e191
        • Karger R.
        • Weippert-Kretschmer M.
        • Budde U.
        • Kretschmer V.
        Diagnosis and therapeutic management in a patient with type 2B-like acquired von Willebrand syndrome.
        Blood Coagul Fibrinolysis. 2011; 22: 144-147
        • Franchini M.
        • Veneri D.
        • Lippi G.
        The use of recombinant activated factor VII in congenital and acquired von Willebrand disease.
        Blood Coagul Fibrinolysis. 2006; 17: 615-619